Santis, M. D., Shore, N. D., Nishiyama, H., Krawczyński, M., Seyitkuliev, A., Guerrero-Ramos, F., Zukov, R., Kawahara, T., Goeman, L., Powles, T., Gust, K. M., Feyerabend, S., Patel, M., Kulkarni, G. S., Lebret, T., Westgeest, H. M., Quartilho, A., Dabrowska, A., Marsh, A., Palou, J. (2026). Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4624